Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.53 and traded as low as $1.1570. Galmed Pharmaceuticals shares last traded at $1.2050, with a volume of 194,440 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GLMD shares. Wall Street Zen downgraded Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Galmed Pharmaceuticals currently has a consensus rating of “Reduce”.

Galmed Pharmaceuticals Stock Down 2.3%

The firm has a 50 day simple moving average of $1.41 and a two-hundred day simple moving average of $1.53. The stock has a market capitalization of $1.99 million, a P/E ratio of -0.52 and a beta of 0.49.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.